Therapeutic Nanoparticles for Renal Disease

Case ID:

University of Arizona researchers have developed a technology that uses biodegradable, polymeric nanoparticles to specifically deliver drugs to the kidney, thereby bypassing off target/organ effects. For example, drugs such as formoterol, a beta 2 adrenergic agonist, can be used to treat acute and chronic renal disease.  Encapsulation of these drugs into nanoparticles targets them to the kidney and prevents cardiovascular side effects that come from traditional drugs of these type.

Renal disease can be treated with a range of drugs classified as beta 2 adrenergic agonists; however, these drugs do not specifically target the kidney.  Encapsulation of these drugs into nanoparticles made from FDA-approved biocompatible and biodegradable polymers (PLGA and PLFA-PEG) targets them to the kidney and prevents cardiovascular side effects.


  • Delivery of drugs to the kidney 
  • Treatment for acute and chronic kidney disease


  • Far less adverse cardiac side-effects than comparable drug delivery methods for renal disease
  • Nanoparticles offer accurate and precise delivery to appropriate tissues
  • Promising potential as a preventative measure for renal disease
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Rick Schnellmann
Heidi Mansour
David Encinas Basurto
Ernest Vallorz